ArticleDrug and alcohol review2025
Estimating the Prevalence of Fetal Alcohol Spectrum Disorder in Australia.
Article in Drug and alcohol review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Implementing the Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach with Children with Fetal Alcohol Spectrum Disorder: A Feasibility Study.Children (Basel, Switzerland) · 2026Article
- Fetal Alcohol Spectrum Disorder Awareness, Knowledge, and Practice Among Australian Occupational Therapists: A Cross-Sectional Survey.Australian occupational therapy journal · 2026Article
- Media portrayals of alcohol use in pregnancy and fetal alcohol spectrum disorder: A scoping review.Alcohol, clinical & experimental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionFetal alcohol spectrum disorder (FASD) is caused by prenatal alcohol exposure (PAE) and characterised by severe neurodevelopmental impairment. Australian studies have reported PAE prevalence of between 14% and 78% of births. Estimating national FASD prevalence in the general population using gold-standard active case ascertainment is costly and time-consuming, and alternative approaches are required.
methodsUsing a published equation for the risk of FASD following PAE (estimated from an international meta-analysis) and a pooled estimate of PAE prevalence in Australia (from a meta-analysis of 78 studies reporting 16 large general population-based birth cohorts between 1975 and 2018), we estimated the population prevalence of FASD. Monte Carlo simulations were used to determine confidence intervals.
resultsEstimated FASD prevalence in the general population was 3.64% (95% confidence interval 2.91%, 4.41%). DISCUSSION AND
conclusionsThe estimated FASD prevalence in the general population of Australia was comparable to that in other high-income countries (e.g., USA, Canada). Although it is likely that certain vulnerable populations have significantly higher FASD prevalence, this estimate provides a baseline estimate for the general population to inform service development and strategies for prevention of FASD and guide future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.